Since 2020, UTRGV researchers have been using the Spingenix SG100-CCS1000 electrospinning system to support cancer nanomedicine development. Now, backed by a $2.8M grant from the Cancer Prevention and Research Institute of Texas (CPRIT), UTRGV has launched the Drug Delivery and Nanomedicine Core (DDNC) at its South Texas Center of Excellence in Cancer Research.
The DDNC will accelerate breakthroughs in targeted cancer therapies, gene delivery, and nanofiber technologies—directly addressing high cancer rates in the Rio Grande Valley. With SG100-CCS1000 as part of its research toolkit, the new core is set to drive innovation and collaboration across disciplines.